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All trans-retinoic acid (ATRA) is widely used to direct the differentiation of cultured 
stem cells.  When exposed to the pluripotent human embryonal carcinoma (EC) stem 10 
cell line, TERA2.cl.SP12, ATRA induces ectoderm differentiation and the formation of 
neuronal cell types. We report in this study that novel polyene chain length analogues of 
ATRA require a specific chain length to elicit a biological responses  of the EC cells 
TERA2.cl.SP12, with synthetic retinoid AH61 being particularly active, and indeed 
more so than ATRA. The impacts of both the synthetic retinoid AH61 and natural 15 
ATRA on the TERA2.cl.SP12 cells were directly compared using both RT-PCR and 
Fourier Transform Infrared Micro-Spectroscopy (FT-IRMS) coupled with multivariate 
analysis. Analytical results produced from this study also confirmed that the synthetic 
retinoid AH61 had biological activity comparable or greater than that of ATRA. In 
addition to this, AH61 has the added advantage of greater compound stability than 20 
ATRA, therefore, avoiding issues of oxidation or decomposition during use with 
embryonic stem cells.
Introduction  
There are over 4000 retinoids, both natural and synthetic, 
structurally and often biochemically related to vitamin A.1 All-25 
trans-retinoic acid 1 (ATRA), the major metabolite of vitamin A, 
and its two isomers, 9-cis-retinoic acid 2 (9CRA) and 13-cis-
retinoic acid 3 (13CRA), have essential roles in many biological 
processes during both chordate embryogenesis and adult 
homeostasis.2,3 These include cellular differentiation,  30 
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proliferation and apoptosis,4 embryonic development5 and 
vision.6 Due to the ability of retinoids to control differentiation 
and apoptosis in both normal and tumour cells, they have the 50 
potential to act as chemopreventative and chemotherapeutic 
agents, although toxicity has prevented widespread use.7,8 ATRA 
and other commercially available retinoids are, however, used to 
treat dermatological conditions.9   
The use of retinoic acids as inducers of cell 55 
differentiation has some limitations, exemplified by ATRA which 
readily isomerises resulting in mixtures of ATRA, 9CRA, 13CRA 
and other species.10 This instability derives from the five 
conjugated double bonds that absorb light in the 300-400 nm 
region, which can occur under laboratory lighting conditions.11-14 60 
Murayama et al.11 reported that isomers of ATRA differently 
affect the ability of mammalian stem cells to differentiate along 
alternative lineages. Consequently this can lead to the differential 
regulation of alternative key molecular pathways involved in 
cellular development, which can result in increased heterogeneity 65 
within cultures of differentiating stem cells.15,16 In order to 
increase reproducibility in the differentiation process, stable 
retinoid derivatives are desirable, an approach adopted by us.10 
These types of stable compounds can maintain a constant 
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concentration in the culture system, and are readily stored and 
handled. This is preferable to the alternative approach of 
attempting to reduce the sensitivity of ATRA to isomerisation by 
the use of additives such as bovine serum albumin (BSA), 
fibrogen, lysozyme, phosphatidylcholine N-ethylmaleimide and 5 
vitamin C.17,18 None of these additives completely suppress 
isomerisation, and indeed, they may affect cellular processes on 
their own. 
 Retinoic acids contain three major characteristic regions: a 
bulky hydrophobic section; a conjugated variable linker; and a 10 
carboxylic acid end group (Fig. 1). Extensive modifications to all 
three regions are possible1,19 and we reported the incorporation of 
an aromatic ring to replace parts of the polyene chain, forming a 
class of retinoids sometimes termed arotinoids.10,19 Another 
common alteration is the inclusion of a 1,1,4,4-tetramethyl-15 
1,2,3,4-tetrahydronaphthalene unit as a substitute for the 
trimethylcyclohexenyl ring and part of the polyene chain, as this 
removes metabolic oxidation sites.19-22 Also, an acetylene moiety 
has been successfully employed to act as a non-isomerisable 
conjugated linker unit while retaining, or even enhancing, 20 
biological activity in systems such as EC23 4a (Fig. 1).10 
Interestingly, biological characterisation of EC23 4a 
demonstrated its ability to induce neural t issues, which contrasts 
with EC19 4b which also induced cell differentiation, the latter 
resulting primarily in epithelial cells with only few neural 25 
phenotypes.10 These results indicated that subtle differences in 
molecular structure can have dramatic effects on the biological 
response. In this paper, we contrast these findings with recent 
work on the design, synthesis, stability and biological activity of 
a series of new synthetic retinoids designed to be closer in 30 
structure to the natural systems 1-3, but with some of the 
increased stability of 4a. With these types of compounds we 
expected to be able to probe further the effects polyene chain 
length and stability versus their effect on cellular development 
processes, particularly in stem cells or models of stem cell 35 
differentiation.  
 
 
 
 40 
 
 
 
 
Fig. 1 Structures for ATRA 1, 9CRA 2, 13CRA 3, generic retinoid 45 
structure, EC23 and EC19. 
 
Results and discussion 
Preparation of retinoid analogues 
It was envisaged that through a series of cross-coupling reactions, 50 
including Heck-Mizoroki and Sonogashira processes, we would 
be able to obtain compounds of varying size to undertake a 
focussed structure activity relationship (SAR) study. Alkyne 5 
was prepared as a generic synthon, starting with iodination of 
1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene, followed by 55 
cross-coupling to TMSA under Sonogashira conditions and 
finally deprotection according to optimised procedures previously 
reported.10 The synthesis of the different polyene chains with 
varying lengths began with the treatment of methyl tetrolate 6 
with sodium iodide in acetic acid23,24 to provide Z-3-iodobut-2-60 
enoic acid methyl ester 7 in 89% yield and 100% 
stereoselectivity. Generation of the E-isomer 8 was achieved 
through isomerisation of the Z-isomer with hydroiodic acid in 
benzene24,25 to give 3-E-iodobut-2-enoic acid methyl ester 8 in a 
66% yield (Scheme 1).  65 
 
CO2Me CO2Me
I
NaI, 
CH3CO2H HI, C6H6
89 % 66%
CO2Me
I
6 7 8  
 
Scheme 1 Synthesis of iodide 8 from methyl tetrolate 6. 
 70 
The E-isomer was subsequently used in two separate reactions: 1) 
direct coupling to acetylene 5 allowing for the formation of 
‘short’ retinoid-like analogue 9; and 2) Heck-Mizoroki coupling 
to vinylboronate ester 10, followed by iododeboronation, leading 
to a dienyliodide 11 for further elaboration to longer derivatives 75 
as outlined in Scheme 2, which employs an iterative Heck-
Mizoroki coupling16 with boronate 10 and highly stereoselective 
iododeboronation methodology.17 Subsequent, Sonogashira 
couplings of iodides 11 and 13 to acetylene 5 under standard 
conditions26,27 provided esters 12 (known as AH61) and 14 in 76 80 
and 64% yields, respectively. Saponification28,29 of the methyl 
esters produced the corresponding carboxylic acids 12 (AH61) 
and 14 in 85 and 87% yields, respectively (Scheme 2).  
 
CO2H
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I
CO2Me
I
CO2H
CO2H
1) 5, Pd(OAc)2, PPh3, CuI,
NEt3, 99%
2) LiOH.H2O (3:1) r.t. 31%
1) 8, Pd(OAc)2, PPh3, CuI,
NEt3, 76%
2) LiOH.H2O (3:1) r.t. 85%
1) 8, Pd(OAc)2, PPh3, CuI,
NEt3, 64%
2) LiOH.H2O (3:1) r.t. 87%
1) 10, AgOAc, 
Pd(OAc)2,
tri(o-toly)phosphine,
MeCN, 74%
2) a) NaOMe, MeOH,
    -78 oC
    b) ICl, DCM, -78 oC,
    - r.t., 86%
1) 10, AgOAc, 
Pd(OAc)2,
tri(o-toly)phosphine,
MeCN, 67%
2) a) NaOMe, MeOH,
    -78 oC
    b) ICl, DCM, -78 oC,
    - r.t., 65%
8
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13
O
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O
10
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 85 
Scheme 2 Synthesis of synthetic retinoids 9, 12 (AH61) and 14 starting 
with iodide 8 and acetylene 5. 
 
Stability of the synthetic retinoids versus natural ATRA 
With the series of synthetic retinoids 9, 12 (AH61) and 14 in 90 
hand, their photostability was tested and compared to that of 
ATRA. We have previously shown, by using 1H NMR 
spectroscopy, that ATRA was susceptible to photoisomerisation 
and degradation when exposed to laboratory (fumehood) 
fluorescent light in the visible to near-UV range. After three days 95 
exposure, substantial isomerisation/degradation occurred with 
approximately 37% of ATRA remaining.10 When the synthetic 
retinoids 9, 12 (AH61) and 14 were exposed to the same 
wavelength of fluorescent light and their 1H NMR spectra 
compared with control (un-irradiated) samples, the severity of the 100 
isomerisation depended greatly upon the length of the conjugated 
linker. The short analogue 9 remained completely unaltered, with 
100% of the original compound present (Fig. 2). The ‘ATRA-
like’ analogue 12 (AH61) showed signs of isomerisation to one 
other isomer identified as (E,Z) but still retained 86% of the 105 
original compound and, more importantly, showed no signs of 
CO2H
CO2H
CO2H
CO2H
CO2H
Conjugated Linker
Polar
Terminus
Hydrophobic 
Unit
1
2
3
4a - EC23
4b - EC19
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degradation unlike previously reported for ATRA (Fig. 3). As 
one might predict, the extended analogue 14 was shown to be the 
least stable, with isomerisation not dissimilar to that seen for 
ATRA (Fig. 4). The inherent instability of ATRA lies within the 
conjugated linker region, as previously established, and 5 
replacement of sections of the polyene chain with both an 
acetylene moiety and phenyl rings as for EC23 4a provides 
complete stability. The stability of the systems 9, 12 (AH61) and 
14 reported here varies as a function of polyene chain length, 
though there is a significant improvement in stability compared to 10 
similarly sized retinoic acids.  
 
 
 
Fig. 2 
1
H NMR at 400 MHz of 9 in DMSO-d
6
 (5.0-8.5 ppm region) in: 15 
Top - in the absence of light and; Bottom- after 3 days exposure to white 
fluorescent light at a distance of 40 cm. 
 
Fig. 3 
1
H NMR at 400 MHz of 12  (AH61) in DMSO-d
6
 (5.0-8.5 ppm 
region) in: Top -in the absence of light and; Bottom - after 3 days 20 
exposure to white fluorescent light at a distance of 40 cm. 
 
 
Fig. 4 
1
H NMR at 400 MHz of 14 in DMSO-d
6
 (5.0-8.5 ppm region) in: 
(A) the absence of light and; (B) after 3 days exposure to white 25 
fluorescent light at a distance of 40 cm. 
 
Effect of the novel retinoids on human pluripotent stem cells  
Having prepared the series of synthetic retinoids 9, 12 (AH61) 
and 14, they were assessed for their ability to induce 30 
differentiation carried out using a human embryonal carcinoma 
(EC) cell line. EC cells are the stem cells of teratocarcinomas, 
and therefore, retain their ability to differentiate into one or more 
of the embryonic germ layers. One of the earliest and most 
frequently used human EC cell lines is the TERA2 cell line, 35 
originally isolated from a lung metastasis originating from a 
testicular germ cell tumour.30 A subsequent sub-clone culture, 
termed TERA2.cl.SP12, was developed in 2001 by 
immunomagnetic isolation followed by single cell selection and 
culture.31 This cell line was chosen for our study, because it has 40 
been shown to differentiate in response to ATRA. After 21 days 
of co-culture with ATRA a heterogeneous cell population was 
visualised containing multiple mature functioning neurons.32-34 
Consequently, this makes the TERA2.cl.SP12 cell line an 
effective model system for the in vitro study of neurogenesis.  45 
 To compare the effect of the synthetic retinoids 9, 12 (AH61) 
and 14 versus both known natural retinoid responses and other 
synthetic retinoids previously synthesised within the group, 
cultures of TERA2.cl.SP12 EC cells were incubated with 10 M 
concentrations of each compound synthesised. Simultaneously, 50 
control cultures were assessed consisting of untreated, therefore 
undifferentiated, cells along with cultures exposed to the vehicle, 
DMSO. Induction of cellular differentiation in response to the 
synthetic retinoids was initially evaluated by analysing the 
expression profile of known markers for both stem cell and 55 
differentiated phenotypes (Fig. 5). Flow cytometry analysis was 
performed at 3, 7 and 14 days on cell samples, treated with 10 
M ATRA, 9, 12 (AH61) and 14. The cells were analysed for the 
expression of the stem cell antigens, SSEA-3 (globoseries stage 
specific embryonic antigen-3) and TRA-1-60 (keratin-sulfate-60 
associated glycoprotein stem surface marker), whereby a decrease 
in the expression level of SSEA-3 and TRA-1-60 indicates cells 
committing to differentiation. Simultaneously, as cell lines of the 
TERA2 lineage are well characterised in their ability to form 
neurons in response to ATRA (33,34), flow cytometry was also 65 
used to assess the expression of A2B5 (ganglioseries antigen 
marking early-stage neural cells), a marker which is expressed 
during the early stages of neuronal development. Similar 
expression profiles were visualised for 12 (AH61) as were seen 
for ATRA over the 14 day period (Fig. 5). In cell cultures treated 70 
with the short and extended analogues 9 and 14, expression levels 
of SSEA-3 and TRA-1-60 remained relatively high with A2B5 
staying comparatively low. Consequently, cultures treated with 9 
and 14 were cultured for only 7 days and not through to 14 days 
due to overgrowth (Fig. 5). As both 9 and 14 did not induce any 75 
significant degree of cellular differentiation, all further studies 
were centred on the ATRA-sized analogue 12 (AH61). 
 Further assessment of cellular differentiation in response to 
synthetic retinoid 12 was evaluated through the expression 
profiles of known genes. Samples from the cells analysed by flow 80 
cytometry at 3, 7 and 14 days after treatment with 10 M 
concentrations of retinoids were simultaneously analysed through 
RT-PCR. Three genes of interest were chosen, i.e. Nanog and 
Oct-4, as gatekeepers of pluripotency, and Pax-6 as a motor and 
ventral neural phenotype. The expression of Nanog and Oct-4 85 
was suppressed in cultures treated with both ATRA and analogue 
12 (AH61), all in a similar manner (Fig. 6). Consistent with these 
observations, Pax-6 expression increased to up to and just after 
day 7, after which it decreased slightly to day 14. Again both 
natural retinoid and synthetic analogue showed a similar profile 90 
(Fig. 6). 
 
 
 
 95 
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A SSEA-3 
 
B TRA-1-60 
 
C A2B5 
 
Fig. 5 Flow cytometric analysis of the induction of TERA2.cl.SP12 cell 
differentiation in response to retinoids. Markers of stem cells (SSEA-3 
and TRA-1-60, A and B respectively) and neural differentiation (A2B5, 
C) were differentially regulated during the 14 day culture period in 5 
response to 10 M ATRA, 9, 12 and 14. Both ATRA and 12  (AH61) 
resulted in a rapid decrease in expression of the stem cell markers and 
reciprocal increase in neural marker expression after 14 days. Treatment 
with 9 and 14 did not induce differentiation; cells continued to proliferate 
and the experiment was terminated after 7 days as a results of being over-10 
confluent. Data represent mean ± SEM, n = 3. 
 
IR imaging of human pluripotent stem cells treated with 
novel retinoid derivatives 
Results from the biological assays, Figs. 5 and 6, clearly show 15 
that the synthetic retinoid 12 (AH61) and ATRA induce the 
differentiation of the TERA2.cl.SP12 cells in a similar manner, 
whereas, retinoids 9 and 14 do not. Recently, Clemens et al.35 
successfully used Fourier Transform Infrared Microspectroscopy 
(FT-IRMS) coupled with multivariate analysis to distinguish 20 
TERA2.cl.SP12 cells from their differentiating derivatives. An 
infrared absorption spectrum of a molecule is characteristic of the 
structure and bonding within the molecule and thus represents a 
molecular fingerprint. The infrared spectrum of a biological cell 
contains a superposition of spectra from all the molecules within 25 
the cell and, although these cannot be separated, the overall 
pattern is nevertheless characteristic of the cell. The technique 
can therefore be used to identify different cell types or to identify 
induced cellular changes such as differentiation.  Accordingly, we 
used FT-IRMS to further assess and validate the biological 30 
activity of synthetic retinoid 12 (AH61). 
  
A Nanog 
 
B Oct4 
 
C Pax 6 
 
 
Fig. 6 RT-PCR analysis of the induction of TERA2.cl.SP12 cell 
differentiation in response to retinoids. Genes associated with 35 
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pluripotency (Nanog and Oct 4, A and B respectively) and  motor and 
ventral neural phenotype (Pax 6, C) were differentially regulated during 
the 14 day culture period in response to 10 M ATRA and 12 (AH61). 
Both ATRA and 12 (AH61) resulted in a rapid decrease in expression of 
the pluripotency genes and reciprocal increase in the motor and ventral 5 
neural gene after 14 days. Data represent mean ± SEM, n = 3.  
 
Fig. 7 (a) shows that cells, 7 days after treated synthetic retinoid 
12 (AH61), can be distinguished from the pluripotent stem cells 
using FT-IRMS coupled with Principle Component Linear 10 
Discriminant Analysis (PC-LDA). The biochemical changes of 
the differentiating cells are described in Fig. 7 (b). 
 
(a) 
 
(b) 
 
(c) 
 
 
Fig. 7 (a) PC-LDA analysis, 2 PCs extracted, spectra transformed to 15 
second derivative and then auto-scaled. Histograms display where the 
DMSO and synthetic retinoid 12 (AH61) treated TERA2.cl.SP12 cells lie 
in the LDA 1 scores plot after 7 days; (b) (upper curve) LDA 1 spectral 
loading, which shows the wavenumbers that contribute to the separation 
seen from the PC-LDA analysis (lower curves) mean spectra of the 20 
DMSO and 12 (AH61) treated cells (fingerprint spectral range); (c) mean 
spectral comparison of the DMSO and 12 (AH61) treated cells (protein 
spectral range). (Note that a positive absorption band will appear as a 
negative "peak" in the second derivative but at the same wavenumber 
position as the original). 25 
 
In the LDA 1 spectral loading, Fig.7 (b), absorpt ion increases at 
wavenumbers associated with proteins (1234, 1286, 1315, 1337 
cm-1) can be seen from cells treated with 12 (AH61) when 
compared to those of the undifferentiated stem cells.36 Protein 30 
changes can also be seen from the mean spectral differences 
shown as second derivatives in Fig.7 (c). The negative "peaks" at 
1640 and 1660 cm–1 (components of the Amide I band which is 
very sensitive to secondary protein structure) are indicative of 
beta sheet and alpha helix conformations, respectively. Clearly, 35 
the cells treated with 12 (AH61) have an increased level of alpha 
helix structure proteins compared with the control 
TERA2.cl.SP12 stem cells.   
 
(a) 
 
(b) 
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Fig. 8 (a) PC-LDA of TERA2.cl.SP12 cells treated with ATRA (green), 
EC23 (blue) and 12 (AH61) (cyan) at day 7, 3 PCs extracted (b) PC-
LDA of TERA2.cl.SP12 cells treated DMSO (black), ATRA (green), 
EC23 (blue) and 12 (AH61) (cyan) at day 7, 10 PCs extracted. 
The LDA 1 spectral loading also shows decreases in absorption 5 
associated with RNA at 1120 (symmetric stretching of the 
phosphodiester band of RNA)37 and 1367-69 cm-1 (C-N stretching 
vibration associated with cytosine and guanine).36 These overall 
changes in net RNA and protein content from the cells treated 
with 12 (AH61) may be a sign of mRNA stores being used up 10 
and transcription occurring to direct the synthesis of specific 
proteins as a result of induction and progression of cellular 
differentiation. 
 
(a) 
 
(b) 
 
(c) 
 
Fig. 9 Mean spectral comparisons of ATRA, 12 and DMSO treated 15 
TERA2.cl.SP12 cells: (a) Lipid spectral range (2830 – 3010 cm-1); (b) 
Fingerprint spectral range (1000 – 1475 cm-1) (c) Protein spectral range 
(1475 – 1760 cm-1.  
Spectra recorded from the TERA2.cl.SP12 cells treated with 12 
(AH61) were also compared against cells treated with ATRA, and 20 
EC23, at 7 days using PC-LDA, Fig. 8. The LDA scores plot 
clearly shows that spectra recorded from the retinoid treated cells 
(blue, cyan , green) can be distinguished from the pluripotent 
stem cells (black) in LDA scores space. Figs. 8 and 9 also show 
that the TERA2.cl.SP12 cells treated with both ATRA and the 25 
synthetic retinoid 12 (AH61) are biochemically similar, 7 days 
after the introduction of the retinoids indicated by the virtual 
overlap of the cyan and green data. This in agreement with both 
the flow cytometry and RT-PCR analysis results seen in Figs. 5 
and 6, respectively. 30 
    Biological assays, such as flow cytometry and RT-PCR, are 
seen as the industry standard and are commonly used when 
discriminating stem cells from their differentiating derivatives. 
However, these biological assays can be laborious and have been 
shown to have some drawbacks.38 Results seen from the FT-35 
IRMS analysis are in agreement with those seen from the 
biological assays and these were achieved without intensive 
sample preparation, relatively cheaply, and very importantly, 
quickly. As an infrared absorption spectrum of a cell contains 
information of the macromolecular composition, protein, lipid, 40 
carbohydrate and nucleic acid changes from differentiating cells 
can be explained. This therefore shows the potential of FT-IRMS 
in screening stem cells and their differentiating derivatives. The 
information obtained can be seen as complementary to biological 
assays when investigating cell differentiation and understanding 45 
cellular development. Because of the speed of FT-IRMS, it is 
possible that it may be favoured when looking at the effect of 
new synthetic retinoids on known embryonic model systems.  
 
Summary and conclusions 50 
Our findings further underline the value of understanding how the 
structure of retinoid analogues relates to their biological activity.  
In this study we report on the importance of polyene chain length 
in relation to compound stability and their effect on cellular 
differentiation by human pluripotent stem cells.  Increasing the 55 
polyene chain length resulted in enhanced compound instability 
and levels of isomerisation proportional to the degree of such 
structural modification.  Lengthening of the polyene linker region 
resulted in isomerisation not dissimilar to that seen for ATRA.  In 
terms of induction of biological activity, a short chain length did 60 
not provoke a biological response (compound 9).  The longest 
chain length we tested (compound 14) induced only a small 
partial cellular response that was most likely the result of a 
mixture of compounds produced from the isomerised parent 
molecule.  In relation to the molecular structures tested, the 65 
optimal structure of the polyene linker region appears to be of 
medium chain length [compound 12 (AH61)] in between that of 
retinoids 9 and 14.  Using conventional molecular methods and 
FT-IRMS, we showed that synthetic retinoid 12 (AH61) showed 
biological activities comparable to ATRA.  However unlike 70 
ATRA, compound 12 (AH61) remained mostly intact during the 
compound stability tests and showed only mild isomerisation. 
   In conclusion, we have further demonstrated how 
understanding the structure activity relationship of synthetic 
retinoids plays an important role in compound design. Moreover, 75 
compound 12 (AH61) represents a potentially useful tool for 
biological investigations avoiding the issues of severe compound 
isomerisation experienced by ATRA whilst conserving a high 
level of biological activity. 
 80 
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Experimental 10 
General synthetic chemistry 
All cross-couplings were carried out under an argon atmosphere 
using standard Schlenk techniques unless otherwise stated. Other 
reactions were performed in the air in reagent-grade solvents. The 
compound 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene 15 
acetylene 5 was prepared according to the literature.10 
Trimethylsilylacetylene was obtained from Fluorochem, methyl 
propiolate and methyl tetrolate from Aldrich, and 4,4,6-trimethyl-
2-vinyl-1,3,2-dioxaborane 10 from Frontier Scientific.  
    Dry solvents were dried by the use of a commercial solvent 20 
purification system (SPS). Petroleum ether (40:60) refers to the 
fraction of petroleum ether that boils between 40 and 60 °C. 
Where mixtures of solvents have been used for chromatography, 
the ratios given refer to volumes used. Thin layer 
chromatography (TLC) was performed on Polygram SIL 25 
G/UV254 plastic backed silica gel plates. Visualisation was 
achieved using a UV lamp at 254 nm, or staining with basic 
potassium permanganate. Column chromatography was carried 
out at medium pressure using silica gel, 40-60μm, 60Å obtained 
from Alfa Aesar. 1H NMR spectra were obtained in CDCl3, 30 
unless otherwise stated, at 400, 500 or 700 MHz on Varian 
Mercury-400, Varian Inova-500 or Varian VNMRS 700 MHz 
spectrometers respectively. Spectra are reported as chemical shift 
δ (ppm) (number of protons, multiplicity, coupling constant J 
(Hz), assignment). All peaks are reported using the residual protic 35 
solvent peak of CHCl3 (δH = 7.26 ppm), as an internal reference. 
13C NMR spectra were obtained in CDCl3 at either 126 or 176 
MHz on Varian Inova-500 or Varian VNMRS 700 MHz 
spectrometers, respectively. All peaks are reported using the 
residual protic solvent peak of CHCl3 (δC = 77.00 ppm) as an 40 
internal reference. 11B NMR spectra were recorded at 128 MHz 
on a Bruker Avance-400 spectrometer in ppm with respect to 
external BF3.OEt2. IR spectra were recorded on a Perkin-Elmer 
Paragon 1000 FT-IR Spectrometer. EI-MS analyses were 
performed on an Agilent 6890N GC equipped with a 5973N 45 
MSD Performance Turbo CI running an EI mode, and an 
Anatune Focus Autosampler/liquid handler, using UHP helium as 
the carrier gas. ES-MS analyses were performed on a Thermo-
Electron Corp. Finnigan LTQ-FT mass spectrometer, using the 
electrospray in positive ion mode (ES+) to generate ions. 50 
Elemental analyses were obtained using an Exeter Analytical CE-
440 analyser. Melting points were obtained using a Gallenkamp 
melting point apparatus. 
 
(Z)-3-Iodobut-2-enoic acid methyl ester 7 55 
Methyl tetrolate 6 (900 mg, 9.2 mmol), NaI (2.4 g, 16 mmol) and 
acetic acid (6 mL) were heated to reflux for 1.5 h, poured onto 
water (20 mL) and extracted with ether (2 x 30 mL). The 
combined organic extracts were washed with saturated NaHCO3 
(3 x 20 mL), 5% NaS2O3 (20 mL) and brine (20 mL). Drying 60 
(MgSO4) and evaporation yielded (Z)-3-iodobut-2-enoic acid 
methyl ester 7 as a clear oil (1.87 g, 90%). All spectroscopic and 
analytical properties were identical to those reported in the 
literature.39 
 65 
(E)-3-Iodobut-2-enoic acid methyl ester 8 
A solution of (Z)-3-iodobut-2-enoic acid methyl ester 7 (4.38 g, 
19.4 mmol) and HI (0.25 g, 1.94 mmol) in benzene (40 mL) were 
heated to reflux for 48 h and then allowed to cool to room 
temperature. The mixture was partitioned between water (100 70 
mL) and ether (150 mL), followed by the aqueous phase being 
extracted with ether (2 x 25 mL). The combined organic phases 
were then washed with saturated NaHCO3 (50 mL), 5% NaS2O5 
(50 mL) and brine (50 mL). Drying (MgSO4) and evaporation 
yielded the crude as a pale yellow oil. Purification by silica gel 75 
chromatography (EtOAc: pet. ether, 5:95, as eluent) yielded (E)-
3-iodobut-2-enoic acid methyl ester as a colourless oil (1.10 g, 
25%) and recovered (Z)-3-iodobut-2-enoic acid methyl ester 
(2.90 g, 66%). All spectral and analytical properties were 
identical to those reported in the literature.39 80 
 
(2E,4E)-3-Methyl-5-(4,4,6-trimethyl-[1,3,2]-dioxaborinan-2-
yl)-penta-2,4-dienoic acid methyl ester 
To a dried Schlenk tube under a positive pressure of argon was 
added (E)-3-iodobut-2-enoic acid 8  methyl ester (0.941 g 4.16 85 
mmol), dry MeCN (15 mL), Pd(OAc)2 (47 mg, 0.21 mmol), tri(o-
tolyl)phosphine (128 mg, 0.42 mmol), AgOAc (758 mg, 4.54 
mmol) and vinylboronate 10 (752 mg, 0.81 mL, 4.88 mmol), the 
mixture degassed using freeze-pump-thaw method (3 x) and 
heated to 55 C with vigorous stirring. After 22 h the mixture was 90 
cooled, diluted with Et2O (80 mL), passed through Celite, washed 
with 5% HCl (20 mL), water (40 mL) and brine (40 mL). Drying 
(MgSO4) and evaporation gave the crude product as a orange oil. 
Purification by silica gel chromatography (EtOAc: pet. ether, 1:9 
as eluent) gave (2E,4E)-3-methyl-5-(4,4,6-trimethyl-[1,3,2]-95 
dioxaborinan-2-yl)-penta-2,4-dienoic acid methyl ester (780 mg, 
74%) as a clear oil; max/cm
-1 2976, 2359, 1710, 1596, 1393, 
1327, 1290, 1229 and 1153; 1H NMR (700 MHz, CDCl3) H 1.28 
(3H, d, J 6, CH3), 1.30 (3H, s, CH3), 1.31 (3H, s, CH3), 1.51 (1H, 
t, J 13, CH2), 1.80 (1H, dd, J 13 and 2.5, CH2), 2.25 (3H, d, J 1, 100 
CH3), 3.70 (3H, s, OCH3), 4.21-4.27 (1H, m, CH), 5.87 (1H, s, 
CH), 5.93 (1H, d, J 18, CH) and 6.92 (1H, d, J 18, CH); 13C 
NMR (176 MHz, CDCl3) C 13.5, 23.3, 28.3, 31.4, 46.1, 51.3, 
65.2, 71.3, 121.0, 129-130, 149.2, 153.2, 167.8; 11B NMR (128 
MHz, CDCl3) B 26 (br s); m/z (ES) 252.1643 (M
+, C13H21BO4, 105 
requires 252.1642). 237, 221, 196, 152, 137, 124 and 83.  
 
Methyl (2E,4E)-5-iodo-3-methylpenta-2,4-dienoate 11 
To a dried Schlenk tube under a positive pressure of argon was 
added a solution of the 2E,4E)-3-methyl-5-(4,4,6-trimethyl-110 
[1,3,2]-dioxaborinan-2-yl)-penta-2,4-dienoic acid methyl ester  
(700 mg, 2.78 mmol), in dry THF (10 mL), and the tube cooled to 
-78 oC in the absence of light. NaOMe (6.91 mL of a 0.5 M 
solution in MeOH, 3.46 mmol) was added dropwise and the 
mixture stirred for 30 mins, followed by the addition of ICl (4.67 115 
mL of a 1.0 M solution in DCM, 4.67 mmol) dropwise. The 
mixture was stirred for 1 h, warmed to room temperature, diluted 
with Et2O (80 mL), washed with 5% sodium metabisulphite (30 
mL), water (30 mL) and brine (30 mL). Drying (MgSO4) and 
evaporation gave the crude product as a orange oil. Purification 120 
by silica gel chromatography (EtOAc:pet. ether, 1:9, a eluent), 
gave the product as a clear oil, which slowly crystallised as an 
off-white solid (602 mg, 86%); All spectral and analytical 
properties were identical to those reported in the literature.39 
max/cm
-1 3070, 3013, 2943, 1708, 1612, 1433, 1386, 1359, 1234, 125 
1190 and 1153; 1H NMR (400 MHz, CDCl3) H 2.24 (3H, d, J 
1.2, CH3), 3.71 (3H, s, OCH3), 5.74 (1H, q, J 0.8, CH), 6.89 (1H, 
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d, J 15, CH), 7.10 (1H, d, J 15, CH); 13C NMR (126 MHz, 
CDCl3) C 13.6, 51.5, 84.8, 120.0, 148.5, 151.4, 167.2; m/z (EI) 
252 (M +), 221, 193, 126 and 125. 
 
(2E,4E)-2-Methyl-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-5 
naphthalen-2-yl)-hepta-2,4-dien-6-ynoic acid methyl ester 
The dienyl iodide 11 (500 mg, 1.98 mmol), 6-ethynyl-1,1,4,4-
tetramethyl-1,2,3,4-tetrahydronaphthalene 5 (509 mg, 2.40 mmol) 
and triethylamine (10 mL) were added to a dried Schlenk tube 
and the mixture degassed using the freeze-pump-thaw method 10 
(3x). Pd(OAc)2 (22 mg, 0.10 mmol), PPh3 (52 mg, 0.19 mmol) 
and CuI (38 mg, 0.19 mmol), were then added and the mixture 
degassed by freeze-pump-thaw (3x). The mixture was stirred at 
room temperature for 5 h, diluted with EtOAc (80 mL), passed 
through Celite, washed with 5% HCl (20 mL 2 x), brine (20 mL), 15 
dried (MgSO4) and concentrated. Purification by silica gel 
chromatography (pet. ether:EtOAc, 95:5, as eluent) gave (2E,4E)-
2-methyl-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-
yl)-hepta-2,4-dien-6-ynoic acid methyl ester as a yellow oil (510 
mg, 76%); max/cm
-1 2956, 2192, 1715, 1608, 1490, 1434, 1358, 20 
1232 and 1154; 1H NMR 500 MHz, CDCl3: H 1.27 (6H, s, 2x 
CH3), 1.28 (6H, s, 2x CH3), 1.68 (4H, s, 2x CH2), 2.31 (3H, d, J 
1.2, CH3), 3.73 (3H, s, OCH3), 5.84 (1H, s, CH), 6.24 (1H, d, J 
16, CH), 6.70 (1H, d, J 16, CH), 7.21 (1H, dd, J 1.5 and 8, Ar), 
7.26 (1H, d, J 8, Ar), 7.41 (1H, d, J 1.5, Ar); 13C NMR (126 25 
MHz, CDCl3) C 13.4, 31.9, 32.0, 34.5, 34.6, 35.1, 35.1, 51.5, 
87.6, 96.0, 114.7, 120.1, 120.4, 127.0, 128.9, 130.3, 143.7, 145.4, 
146.3, 151.4, 167.4; m/z (ES) 337.2164 (M  + H+, C23H29O2, 
requires 337.2162), 337, 305 and 215.       
 30 
(2E,4E)-2-Methyl-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)-hepta-2,4-dien-6-ynoic acid 12 (AH61) 
(2E,4E)-2-Methyl-7-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)-hepta-2,4-dien-6-ynoic acid methyl ester (0.51 
g, 1.49 mmol), was dissolved in a THF water mixture (3:1, 20 35 
mL) followed by the addition of LiOH.H2O (250 mg, 5.94 
mmol). The mixture was stirred at room temperature for 48 h in 
the absence of light after which the reaction was judged to be 
complete by tlc. The mixture was then acidified to pH 1 by the 
addition of HCl (20%), and extracted with diethyl ether (20 mL, 40 
2x). The sample was evaporated to give the crude product as a 
yellow powder. This was re-crystallised from acetonitrile to yield 
the product as a yellow crystalline solid (394 mg, 82%); m.p. 
205.1-206.7 °C;  max/cm
-1 2500-3500, 2194, 1679, 1604, 1488, 
1459, 1255 and 1185; 1H NMR: (700 MHz, CDCl3) H 1.27 (6H, 45 
s, 2x CH3), 1.28 (6H, s, 2x CH3), 1.68 (4H, s, 2x CH2), 2.32 (3H, 
d, J 1, CH3), 5.87 (1H, s, CH), 6.29 (1H, d, J 16, CH), 6.73 (1H, 
d, J 16, CH), 7.21 (1H, dd, J 1.5 and 8, Ar), 7.27 (1H, d, J 8, Ar), 
7.41 (1H, d, J 1.5, Ar); 13C NMR: (126 MHz, CDCl3) C 13.6, 
31.9, 32.0, 34.4, 34.6, 35.1, 35.1, 87.5, 96.6, 115.6, 119.9, 120.0, 50 
127.0, 129.0, 130.3, 143.5, 145.4, 146.4, 153.7, 172.0; m/z (ES) 
321.1858 (M -, C22H26O2, requires 321.1860), 260, 186, 159 and 
91; Anal. Calcd for C22H26O2: C, 81.95; H, 8.13. Found: C, 
81.87; H, 8.10.  55 
(E)-3-Methyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)-pent-2-en-4-ynoic acid methyl ester 
To a dried Schlenk flask flask under a positive pressure of argon 
was added (E)-3-iodobut-2-enoic acid methyl ester 11 (0.36 g, 
1.72 mmol), 6-ethynyl-1,1,4,4-tetramethyl-1,2,3,4-60 
tetrahydronaphthalene 5 (0.40 g, 1.88 mmol) and Et3N (10 ml). 
The mixture was degassed using the freeze-pump-thaw method 
(3x), followed by the addition of Pd(OAc)2 (20 mg, 0.08 mmol), 
PPh3 (44 mg, 0.16 mmol) and CuI (32 mg, 0.16 mmol). The 
mixture degassed using the freeze-pump-thaw method (2x) and 65 
stirred at room temperature under argon. After 24 h, the reaction 
was diluted with Et2O (80 ml), passed through Celite, washed 
with 5% HCl (20 ml, 2x), brine (20 ml), dried (MgSO4) and 
evaporated to give an orange oil. Purification by silica gel 
chromatography (EtOAc:petroleum ether, 5:95, as eluent) gave 70 
(E)-3-methyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)-pent-2-en-4-ynoic acid methyl ester as a pale 
yellow oil (530 mg, 99%). max/cm
-1 2957, 2195, 1715, 1612, 
1433, 1342, 1269, 1198, 1180 and 1135; 1H NMR (700 MHz, 
CDCl3)  1.27 (6H, s, 2x CH3), 1.28 (6H, s, 2x CH3), 1.68 (4H, s, 75 
2x CH2), 2.40 (3H, d, J 1.5, CH3), 3.73 (3H, s, OCH3), 6.15 (1H, 
q, J 1.5, CH), 7.21 (1H, dd, J 8 and 1.5, Ar), 7.27 (1H, d, J 8, Ar), 
7.41 (1H, d, J 1.5, Ar); 13C NMR (176 MHz, CDCl3) C 20.3, 
31.9, 32.0, 34.5, 34.7, 35.1, 35.1, 51.5, 90.5, 94.9, 119.4, 123.4, 
127.0, 129.2, 130.5, 138.8, 145.5, 146.8, 166.9; m/z (ES) 80 
311.2011 (M + H+, C21H27O2, requires 311.2006). 279.      
 
(E)-3-Methyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-
naphthalen-2-yl)-pent-2-en-4-ynoic acid 9 
(E)-3-Methyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-85 
naphthalen-2-yl)-pent-2-en-4-ynoic acid methyl ester (85 mg, 
0.274 mmol) was added to a stirred solution of lithium hydroxide 
(46 mg, 1.10 mmol) in THF/H2O (3:1, 20 ml) at room 
temperature. After 48 hours the reaction was judged to be 
complete and acidified to pH 1 to 2 by 20% HCl, extracted with 90 
ether (20 ml), dried (MgSO4) and concentrated to give an off-
white solid. Recrystallisation from acetonitrile yielded the 
product as an off-white crystalline solid (25 mg, 31%). max/cm
-1 
2912, 2197, 1688, 1602, 1428, 1296, 1225 and 1145; 1H NMR 
(700 MHz, CDCl3)  1.27 (6H, s, 2x CH3), 1.28 (6H, s, 2x CH3), 95 
1.68 (4H, s, 2x CH2), 2.41 (3H, d, J 1.5 CH3), 6.18 (1H, d, J 1.5, 
CH), 7.22 (1H, dd, J 8 and 1.5, Ar), 7.28 (1H, d, J 8, Ar), 7.42 
(1H, d, J 1.5, Ar); 13C NMR (176 MHz, CDCl3) C 20.6, 31.9, 
32.0, 34.5, 34.7, 35.0, 35.1, 90.5, 96.2, 119.3, 122.4, 127.1, 
129.2, 130.6, 141.3, 145.5, 147.0, 169.0; m/z (ES) 296.1773 (M +, 100 
C20H24O2, requires 296.1771), 279, 255, 84 and 43.   
 
(2E,4E,6E)-3-Methyl-7-(4,4,6-trimethyl-[1,2,3]-dioxaborinan-
2-yl)-hepta-2,4,6-trienoic acid methyl ester 
To a dried Schlenk tube under a positive pressure of argon was 105 
added Pd(OAc)2 (16.5 mg, 0.07 mmol), AgOAc (296 mg, 1.61 
mmol), tri(o-tolyl)phosphine (45 mg, 0.148 mmol), methyl 
(2E,4E)-5-iodo-3-methylpenta-2,4-dienoate (0.37 g, 1.47 mmol) 
and acetonitrile (10 ml). The mixture was degassed using the 
freeze-pump-thaw method (2x) followed by the addition of vinyl 110 
boronate 10 (265 mg, 1.72 mmol). The mixture was degassed 
again using the freeze-pump-thaw method before heating to 50 C 
with vigorous stirring. After 22 h, the reaction was cooled to 
room temperature, diluted with Et2O (60 ml), passed through 
Celite, washed with 5% HCl (20 ml), water (40 ml) and brine (20 115 
ml), dried (MgSO4) and evaporated. The product was purified by 
silica gel chromatography (EtOAc:pet. ether, 1:9, as eluent) to 
give the product (2E,4E,6E)-3-methyl-7-(4,4,6-trimethyl-[1,2,3]-
dioxaborinan-2-yl)-hepta-2,4,6-trienoic acid methyl ester as a 
pale yellow oil (274 mg, 67%). max/cm
-1 2973, 1711, 1614, 1391, 120 
1303, 1237, and 1150; 1H NMR (700 MHz, CDCl3) H 1.28 (3H, 
d, J 6, CH3), 1.31 (3H, s, CH3), 1.31 (3H, s, CH3), 1.51 (1H, t, J 
14, CH2), 1.80 (1H, dd, J 14 and 3, CH2), 2.30 (3H, s, CH3), 3.71 
(3H, s, OCH3), 4.21-4.27 (1H, m, CH), 5.68 (1H, d, J 17, CH), 
5.81 (1H, s, CH), 6.36 (1H, d, J 17, CH), 6.63 (1H, dd, J 17 and 125 
11, CH) and 6.99 (1H, dd, J 17 and 11, CH); 13C NMR (176 
MHz, CDCl3) C 13.9, 23.3, 28.3, 31.4, 46.1, 51.2, 65.1, 71.1, 
119.9, 130.0, 132.0, 136.6, 137.9, 146.0, 152.6, 167.5; m/z (ES) 
278.1802 (M +, C15H24BO4, requires 278.1798), 190, 174, 162, 
144, 136, 58, 52 and 44.  130 
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(2E,4E,6E)-7-Iodo-3-methyl-hepta-2,4,6-trienoic acid methyl 
ester 13 
To a dried Schlenk tube under a positive pressure of argon was 
added the (2E,4E,6E)-3-methyl-7-(4,4,6-trimethyl-[1,2,3]-
dioxaborinan-2-yl)-hepta-2,4,6-trienoic acid methyl ester  (0.2 g, 5 
0.72 mmol) in dry THF (5 ml) The mixture was cooled to -78 oC 
in the absence of light, followed by the addition of NaOMe (1.79 
ml of a 0.5 M solution in MeOH, 0.895 mmol). After 30 mins, 
ICl (1.21 ml of a 0.5 M solution in CH2Cl2, 1.21 mmol) was 
added to the mixture and stirred for 1 h. The reaction was 10 
warmed to room temperature, diluted with Et2O (30 ml), washed 
with sodium metabisulphite (30 ml), water (30 ml), and brine (30 
ml), dried (MgSO4) and evaporated to give an orange oil. 
Purification by silica gel chromatography (EtOAc:pet. ether, 1:9, 
cooled to 0 C) yielded the product as a pale yellow oil (131 mg, 15 
65%). max/cm
-1 2946, 1710, 1609, 1557, 1433, 1390, 1357, 1238, 
1189 and 1152; 1H NMR (500 MHz, CDCl3) H 2.31 (3H, d, J 1, 
CH3), 3.73 (3H, s, OCH3), 5.87 (1H, s,  CH), 6.28 (1H, d, J 15, 
CH), 6.51 (1H, ddd, J 15, 11 and 5, CH), 6.62 (1H, d, J 15, CH), 
and 7.16 (1H, ddd, J 15, 11 and 5, CH); 13C NMR (126 MHz, 20 
CDCl3) C 13.8, 51.4, 83.4, 120.7, 133.8, 136.3, 145.0, 151.8, 
167.5; m/z (ES) 277.9799 (M +, C9H11IO2, requires 277.9798), 
247, 219, 127, 91, 65 and 50.    
 
(2E,4E,6E)-3-Methyl-9-(5,5,8,8-tetramethyl-5,6,7,8-25 
tetrahydro-naphthalen-2-yl)-nona-2,4,6-trien-8-ynoic acid 
methyl ester  
The corresponding iodide (60 mg, 0.216 mmol), 6-ethynyl-
1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene 5 (55 mg, 0.26 
mmol) and Et3N (2 ml) were added to a dried schlenk tube and 30 
the mixture degassed using the freeze-pump-thaw method (3x). 
Pd(OAc)2 (2.5 mg, 0.01 mmol), PPh3 (5.5 mg, 0.02 mmol) and 
CuI (4 mg, 0.02 mmol) were then added and the mixture 
degassed using the freeze-pump-thaw method (3x) and stirred at 
room temperature for 5 h. The reaction was diluted with Et2O (60 35 
ml), passed through Celite, washed with 5% HCl (20 ml, 2x), 
brine (20 ml), dried (MgSO4) and evaporated to give an orange 
oil. Purification by silica gel chromatography (pet. ether:EtOAc, 
95:5, as eluent) gave (2E,4E,6E)-3-methyl-7-(4,4,6-trimethyl-
[1,2,3]-dioxaborinan-2-yl)-hepta-2,4,6-trienoic acid methyl ester 40 
as a pale yellow oil (50 mg, 64%).  max/cm
-1 2955, 2181, 1709, 
1604, 1435, 1358, 1240, and 1153; 1H NMR (700 MHz, CDCl3) 
H 1.27 (6H, s, 2x CH3), 1.28 (6H, s, 2x CH3), 1.67 (4H, s, 2x 
CH2), 2.31 (3H, s, CH3), 3.71 (3H, s, OCH3), 5.82 (1H, s, CH), 
5.99 (1H, d, J 15, CH), 6.34 (1H, d, J 15, CH), 6.67 (1H, ddd, J 45 
15, 11 and 4, CH), 6.74 (1H, ddd, J 15, 11 and 4, CH), 7.19 (1H, 
dd, J 8 and 1.5, Ar), 7.27 (1H, d, J 8, Ar), 7.39 (1H, d, J 1.5, Ar); 
13C NMR (176 MHz, CDCl3) C 13.9, 31.9, 31.9, 34.6, 34.6, 35.1, 
35.1, 51.3, 88.2, 95.5, 98.8, 115.0, 120.2, 120.4, 127.0, 128.8, 
130.1, 134.0, 137.5, 140.6, 145.3, 146.1, 167.5; m/z (ES) 50 
363.2322 (M +H+, C25H31O2, requires 363.2319). 331, 289 and 
215.    
  
(2E,4E,6E)-3-Methyl-9-(5,5,8,8-tetramethyl-5,6,7,8-
tetrahydro-naphthalen-2-yl)-nona-2,4,6-trien-8-ynoic acid 14 55 
(2E,4E,6E)-3-Methyl-7-(4,4,6-trimethyl-[1,2,3]-dioxaborinan-2-
yl)-hepta-2,4,6-trienoic acid methyl ester (120 mg, 0.331 mmol) 
was added to a stirred solution of LiOH (42 mg, 0.993 mmol) in 
THF/H2O (3:1, 10 ml) at 4
 C. After the reaction was judged to be 
complete by tlc, the reaction mixture was acidified to pH 1/2 by 60 
20% HCl, extracted with Et2O (20 ml), dried (MgSO4) and 
evaporated to give an orange oil. Purification by silica gel 
chromatography (petroleum ether:EtOAc, 9:1, as eluent) gave the 
product as a yellow solid (100 mg, 87%) and a 2.5:1 mixture of 
alkene diastereoisomers. 1H NMR (700 MHz, CDCl3) H 1.26 65 
(6H, s, 2x CH3), 1.27 (6H, s, 2x CH3), 1.67 (4H, s, 2x CH2), 2.32 
(3H, s, CH3), 5.85 (1H, s, CH), 6.01 (1H, d, J 14, CH), 6.36 (1H, 
d, J 14, CH), 6.73 (2H, ddd, J 14, 11 and 4, 2x CH), 7.19 (1H, dd, 
J 8 and 1.5, Ar), 7.28 (1H, d, J 8, Ar), 7.39 (1H, d, J 1.5, Ar); 13C 
NMR (176 MHz, CDCl3) C 14.1, 31.9, 31.9, 32.0, 34.4, 34.6, 70 
35.1, 35.1, 88.1, 95.8, 99.0, 115.6, 119.4, 120.2, 126.9, 128.8, 
130.2, 134.8, 137.2, 140.5, 145.4, 146.1, 154.4; m/z (ES) 
347.2016 (M + - H, C24H27O2, requires 347.2017).  
  
 75 
 
Exposure to light 
Synthetic retinoid NMR samples were prepared and left to stand 
in ordinary laboratory light, with additional irradiation from a 
standard fluorescent light ca. 30 cm above the sample. 80 
 
Biological Analytical Procedures 
Tissue Culture 
Human pluripotent TERA2.cl.SP12 embryonal carcinoma stem 
cells were maintained under standard laboratory conditions as 85 
previously described (31). In brief, cells were cultured in DMEM 
(Sigma) supplemented with 10% FCS (Gibco), 2mM L-glutamine 
and 100 active units each of penicillin and streptomycin (Gibco). 
Cultures were passaged using acid-washed glass beads (VWR) 
unless a single-cell suspension was required for counting, in 90 
which case a 0.25% trypsin EDTA (Cambrex) solution was used. 
Cultures intended for flow cytometric and RT-PCR analysis were 
set up in T25 flasks (Nunc) while 12-well plates (Nunc) were 
used for immunocytochemical studies and cell viability/apoptopic 
analysis.  95 
 
Flow Cytometry 
Flow cytometry analysis was carried out on live cells using 
antibodies recognising cell surface markers. The expression of 
markers indicative of the stem cell SSEA-3 (University of Iowa 100 
Hybridoma Bank) and TRA-1-60 (generous gift from Prof. P. 
Andrews, University of Sheffield)) or neural cell (A2B5, R&D 
Systems) phenotype was determined to indicate the status of 
cellular differentiation by TERA2.cl.SP12 cells. Suspensions of 
single EC cells of their differentiated derivatives were formed by 105 
the addition of 1 mL 0.25% trypsin/EDTA solution. The cell 
suspension was divided accordingly for flow cytometry and RT-
PCR (see later) analysis accordingly. Cells were added to a 96-
well plate (0.2 x 106 cells per well) as a suspension in wash buffer 
(0.1% BSA in PBS) for incubation with primary (1:20 SSEA-3 110 
and TRA-1-60, or 1:10 A2B5) and FITC-conjugated secondary 
antibody (Cappell, 1:100) as previously described. Labelled cells 
were analysed in a Guave EasyCyte  Plus System (Millipore) 
flow cytometer. Thresholds determining the numbers of 
positively expressing cells were set against the negative control 115 
antibody P3X. 
 
Gene Expression Analysis 
Real time PCR was carried out on cells immediately lysed after 
treatment with 0.25% trypsin/EDTA. Commercial RNA 120 
extraction kits and procedures (Qiagen) and reverse transcription 
procedures (Applied Biosystems) were followed. In brief, cells 
were lysed, homogenised using a 20-gauge needle, and passed 
through an RNeasy spin column. DNase digestion was carried 
out, before the RNA was extracted from the column as a 125 
suspension in RNase free water. Amounts of RNA extracted were 
determined using a Nanodrop Spectrophotometer ND-100 , 
followed by analysis on a 1% Agrose gel to check RNA integrity. 
Reverse transcription was then carried out using a high-capacity 
cDNA reverse transcription kit and a thermal cycler. cDNA was 130 
stored at – 20 oC prior to analysis. RT-PCR was performed using 
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the TaqMan Gene Expression system from Applied Biosystems.  
Probe sets to the specific genes analysed were purchased from 
Applied Biosystems using the AB codes: Oct4 (Hs03005111_g1); 
Nanog (Hs02387400_g1); Pax-6 (Hs00240871_m1). GAPDH 
(4333764F) was used as the internal control gene. Sample 5 
reactions were performed in 96-well plates following the 
manufacturer’s recommended protocol and were run on the 
Applied Biosystems 7500 Fast RT-PCR analyser. 
 
 10 
FTIR Microspectroscopy 
The infrared data were recorded on a Varian 670 FTIR 
spectrometer interfaced with a Varian-620 imaging infrared 
microscope. The microscope was equipped with a 128 × 128 
liquid nitrogen cooled MCT focal plane array detector (FPA) 15 
with a pixel effective size on the sample of 5.5 µm. The infrared 
spectral images were collected in transmission mode (512 scans 
at 4 cm-1 resolution) and the background image was recorded 
from a clean CaF2 slide. Data was processed using the same 
methods described by Clemens et al.35 20 
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